Current Treatment Options in Oncology

, Volume 8, Issue 4, pp 322–330

Radiofrequency Thermal Ablation of Metastatic Neuroendocrine Tumors in the Liver

  • Peter J. Mazzaglia
  • Eren Berber
  • Allan E. Siperstein
Endocrine Tumors

Opinion Statement

In our armamentarium against neuroendocrine hepatic metastases, radiofrequency thermal ablation has proven to play a valuable role. Patients with neuroendocrine malignancies that progress to hepatic metastases may suffer not only from the hormonal sequelae of their disease, but also face the specter of death within several years from progressive hepatic replacement. For the majority of these patients who are not surgical candidates due to the extent of liver involvement, radiofrequency thermal ablation represents a low-risk treatment modality effective at both symptom alleviation and survival prolongation. Utilizing a laparoscopic approach guided by intra-operative ultrasound, effective tumor ablation can be achieved with minimal morbidity and low rates of local tumor recurrence.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: •  Of importance

  1. 1.•
    Touzios JG, Kiely JM, Pitt SC, et al. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 2005; 241(5):776–783; discussion 783–785PubMedCrossRefGoogle Scholar
  2. 2.•
    Sarmiento JM, Heywood G, Rubin J, et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 2003; 197(1):29–37PubMedCrossRefGoogle Scholar
  3. 3.•
    Carty SE, Jensen RT, Norton JA Prospective study of aggressive resection of metastatic pancreatic endocrine tumors. Surgery 1992; 112(6):1024–1031; discussion 1031–1032PubMedGoogle Scholar
  4. 4.
    Lounsberry W, Goldschmidt V, Linke C The early histologic changes following electrocoagulation. J Urol 1961; 86:291–297Google Scholar
  5. 5.
    Buscarini L, Rossi S, Fornari F, et al. Laparoscopic ablation of liver adenoma by radiofrequency electrocautery. Gastrointest Endosc 1995; 41(1):68–70PubMedCrossRefGoogle Scholar
  6. 6.
    Rossi S, Di Stasi M, Buscarini E, et al. Percutaneous radiofrequency interstitial thermal ablation in the treatment of small hepatocellular carcinoma. Cancer J Sci Am 1995; 1(1):73–81PubMedGoogle Scholar
  7. 7.•
    Berber E, Flesher NL, Siperstein AE Initial clinical evaluation of the RITA 5-centimeter radiofrequency thermal ablation catheter in the treatment of liver tumors. Cancer J Sci Am 2000; 6(S4):S319–329Google Scholar
  8. 8.
    Berber E, Siperstein AE Perioperative outcome after laparoscopic radiofrequency ablation of liver tumors: an analysis of 521 cases. Surg Endosc 2007; 21(4):613–618PubMedCrossRefGoogle Scholar
  9. 9.
    Mazzaglia PJ, Berber E, Milas M, Siperstein AE Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery 2007; 142(1):10–19PubMedCrossRefGoogle Scholar
  10. 10.
    Berber E, Flesher N, Siperstein AE Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg 2002; 26(8):985–990PubMedCrossRefGoogle Scholar
  11. 11.•
    Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 2000; 190(4):432–445PubMedCrossRefGoogle Scholar
  12. 12.
    Nave H, Mossinger E, Feist H, et al. Surgery as primary treatment in patients with liver metastases from carcinoid tumors: a retrospective, unicentric study over 13 years. Surgery 2001; 129(2):170–175PubMedCrossRefGoogle Scholar
  13. 13.
    Que FG, Nagorney DM, Batts KP, et al. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 1995; 169(1):36–42; discussion 42–43PubMedCrossRefGoogle Scholar
  14. 14.
    Carrasco CH, Charnsangavej C, Ajani J, et al. The carcinoid syndrome: palliation by hepatic artery embolization. AJR Am J Roentgenol 1986; 147(1):149–154PubMedGoogle Scholar
  15. 15.
    Perry LJ, Stuart K, Stokes KR, Clouse ME Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Surgery 1994; 116(6):1111–1116; discussion 1116–1117PubMedGoogle Scholar
  16. 16.•
    Kvols LK, Moertel CG, O’Connell MJ, et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long- acting somatostatin analogue. N Engl J Med 1986; 315(11):663–666PubMedCrossRefGoogle Scholar
  17. 17.
    Janson ET, Oberg K Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol 1993; 32(2):225–229PubMedCrossRefGoogle Scholar
  18. 18.
    Ruszniewski P, Ducreux M, Chayvialle JA, et al. Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut 1996; 39(2):279–283PubMedCrossRefGoogle Scholar
  19. 19.
    Bilchik AJ, Sarantou T, Foshag LJ, et al. Cryosurgical palliation of metastatic neuroendocrine tumors resistant to conventional therapy. Surgery 1997; 122(6):1040–1047; discussion 1047–1048PubMedCrossRefGoogle Scholar
  20. 20.•
    Proye CA, Lokey JS Current concepts in functioning endocrine tumors of the pancreas. World J Surg 2004; 28(12):1231–1238PubMedCrossRefGoogle Scholar
  21. 21.
    Martin LW, Warren RS Current management of colorectal liver metastases. Surg Oncol Clin N Am 2000; 9(4):853–876; discussion 877–878PubMedGoogle Scholar
  22. 22.
    Carty SE, Jensen RT, Norton JA Prospective study of aggressive resection of metastatic pancreatic endocrine tumors. Surgery 1992; 112(6):1024–1031; discussion 1031–1032PubMedGoogle Scholar
  23. 23.
    Yao KA, Talamonti MS, Nemcek A, et al. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery 2001; 130(4):677–682; discussion 682–685PubMedCrossRefGoogle Scholar
  24. 24.
    Gupta S, Johnson MM, Murthy R, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 2005; 104(8):1590–1602PubMedCrossRefGoogle Scholar
  25. 25.
    Seifert JK, Junginger T, Morris DL A collective review of the world literature on hepatic cryotherapy. J R Coll Surg Edinb 1998; 43(3):141–154PubMedGoogle Scholar
  26. 26.
    O’Toole D, Ruszniewski P Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours. Best Pract Res Clin Gastroenterol 2005; 19(4):585–594PubMedCrossRefGoogle Scholar
  27. 27.
    Oberg K Endocrine tumors of the gastrointestinal tract: systemic treatment. Anticancer Drugs 1994; 5(5):503–519PubMedCrossRefGoogle Scholar
  28. 28.
    Moertel CG Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol 1987; 5(10):1502–1522PubMedGoogle Scholar
  29. 29.
    Kvols LK, Buck M Chemotherapy of metastatic carcinoid and islet cell tumors. A review. Am J Med 1987; 82(5B):77–83PubMedCrossRefGoogle Scholar
  30. 30.
    Foroutani A, Garland AM, Berber E, et al. Laparoscopic ultrasound vs. triphasic computed tomography for detecting liver tumors. Arch Surg 2000; 135(8):933–938PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc. 2007

Authors and Affiliations

  • Peter J. Mazzaglia
    • 1
  • Eren Berber
    • 1
  • Allan E. Siperstein
    • 1
  1. 1.Department of Surgery A-80Cleveland Clinic FoundationClevelandUSA

Personalised recommendations